The O&P EDGE published a practitioner's case for refocusing the field on phantom limb pain. The global treatment gap backs the argument.

An O&P researcher and practitioner writing in the September 2026 O&P EDGE describes a shift in how they think about the field’s most important problems. After years of developing sophisticated prosthetic technology, the most significant lesson, the author writes, came not from the laboratory but from a patient.

The argument the piece opens is not sentimental. It is structural. Phantom limb pain is among the most prevalent consequences of amputation. Effective treatments for it are documented, and in several cases require no specialized infrastructure to deliver. Globally, the gap between the number of people who experience PLP and the number who receive any treatment for it is substantial. That gap is not primarily a technology problem. It is an access and priority problem.

What phantom limb pain is and how common it is

Phantom limb pain is the experience of pain sensations in a limb that is no longer physically present. It is distinct from residual limb pain, which is pain in the remaining portion of the limb itself. Most clinical literature, including the VA and Department of Defense Clinical Practice Guideline for the Management of Phantom Limb Pain, places PLP prevalence somewhere between half and four-fifths of people following amputation.

The mechanism is not fully mapped. The motor cortex continues generating movement signals for a limb that sends back no sensory confirmation. That mismatch, together with changes in the central nervous system following amputation, is thought to drive the pain experience. Why the same anatomical event produces intense chronic pain in some people and little or no PLP in others is still being characterized. What is established is that PLP is not rare, not a psychological response to amputation, and not typically self-resolving without attention.

For a fuller orientation to the condition and its documented management approaches, the desk’s phantom limb pain guide covers the mechanisms and treatment landscape in more detail. The VR research from the University of Georgia published recently covers one emerging technology approach and its relationship to the longer-standing mirror therapy evidence base.

The cost and access asymmetry

Mirror therapy, one of the better-studied non-pharmacological approaches to PLP, requires a mirror. Graded motor imagery, another documented approach, can be delivered in substantial part through a structured exercise protocol that does not require a clinic visit. Neither approach works uniformly across patients, and neither is a guaranteed solution. But both have a meaningful evidence base, and the infrastructure they require is within reach of a wide range of clinical settings, including low-resource ones.

This is worth noting alongside what O&P innovation investment has concentrated on. Microprocessor prosthetic knees, powered ankles, myoelectric arms, sensory feedback integration: the devices that draw the most commercial and research attention are expensive, require specialized fitting, and depend on supply chains and clinic infrastructure that most of the world does not have. The patients served by those innovations are real and the advances are meaningful. But the population who might benefit from better PLP treatment access is much larger, and the per-person cost of effective treatment is, in many documented cases, much lower.

Where the global gap is widest

The majority of amputations worldwide occur in low- and middle-income countries. Diabetes and peripheral vascular disease are the dominant drivers globally. Conflict-related injuries are a significant cause in affected regions. In each of these contexts, amputation rates are high and prosthetic access is limited. The absence of advanced powered devices in those settings is well documented. What draws less attention is that basic pain management for PLP is often equally absent.

That is the version of the treatment gap the O&P EDGE piece points toward: not a failure of technological development, but a failure of deployment for treatments that already exist and could be delivered at low cost.

The argument is uncomfortable in a specific way. The O&P field has genuine and well-funded reasons to pursue device innovation. The clinical outcomes produced by microprocessor prosthetics for people who can access them are real. The problem is not the innovation. It is the mismatch between where the innovation is directed and where the burden of suffering is largest.

What this means

For O&P researchers and funders, the piece raises a question about proportionality. The field’s capacity for sophisticated device innovation has grown substantially over the past two decades. Whether that growth has tracked the distribution of unmet need, or the economics of high-income markets, is a fair question.

For patients in the United States dealing with phantom limb pain, the more immediate point is that documented treatment options exist and that PLP is something to raise directly with your clinical team rather than manage alone. What works varies by individual, and a clinical team can describe which approaches are appropriate given your specific situation. The desk’s phantom limb pain guide covers what to ask and what the current evidence says about each approach.

The O&P EDGE piece does not offer a policy prescription. It offers a perspective from inside the field on where attention should go. The global treatment access numbers for phantom limb pain suggest that perspective is warranted.

---

Medical information on this site is for general context and orientation, not a substitute for individualized clinical advice. Discuss phantom limb pain symptoms and treatment options with your care team.